Hans van Houte sold $86k of NRIX
Chief Financial Officer at Nurix Therapeutics, Inc.. 3,546 shares at an average of $24.28, traded Nov 1, 2024, filed Nov 1, 2024.
Score components
- +22RoleCFO
- +9Trade size$86k at market
- 0Share of holdings soldSold 9.5% of holdings
- +15Cluster3 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -9.6%, 3m -19.5%, 6m -53.9%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001549595-24-000153, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 1, 2024 | SOpen-market sale Common Stock10b5-1 | -3,546 | $24.28 | $86k | 33,724 | Nov 1, 2024 |
Related signals
Other insiders at Nurix Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 1Weak | Nurix Therapeutics, Inc. | Christine Ring Chief Legal Officer | $134k 5,786 shares | -39% | |
| 9Weak | Nurix Therapeutics, Inc. | Christine Ring Chief Legal Officer | $149k 5,787 shares | -39% | |
| 0Weak | Nurix Therapeutics, Inc. | Gwenn Hansen Chief Scientific Officer | $37k 1,452 shares | -1% | |
| 0Weak | Nurix Therapeutics, Inc. | Christine Ring Chief Legal Officer | $67k 3,760 shares | -7% | |
| 10Weak | Nurix Therapeutics, Inc. | Christine Ring Chief Legal Officer | $642k 37,600 shares | -42% | |
| 31Weak | Nurix Therapeutics, Inc. | Hans van Houte Chief Financial Officer | $79k 6,284 shares | -14% | |
| 22Weak | Nurix Therapeutics, Inc. | Gwenn Hansen Chief Scientific Officer | $52k 4,087 shares | -5% | |
| 21Weak | Nurix Therapeutics, Inc. | Christine Ring Chief Legal Officer | $47k 3,644 shares | -7% | |
| 28Weak | Nurix Therapeutics, Inc. | Hans van Houte Chief Financial Officer | $40k 3,130 shares | -7% | |
| 29Weak | Nurix Therapeutics, Inc. | Hans van Houte Chief Financial Officer | $60k 5,402 shares | -13% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.